Mark Joseph Cantwell
Hoofd Techniek/Wetenschap/O&O bij Memgen, Inc.
Profiel
Mark Joseph Cantwell is currently the Chief Scientific Officer & Director at Memgen, Inc. Previously, he worked as the Vice President-Research & Development at Mast Therapeutics, Inc. He completed his undergraduate degree at Georgia Institute of Technology and his doctorate at the University of California San Diego.
Actieve functies van Mark Joseph Cantwell
| Bedrijven | Functie | Begin |
|---|---|---|
Memgen, Inc.
 Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Mark Joseph Cantwell
| Bedrijven | Functie | Einde |
|---|---|---|
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Mark Joseph Cantwell
| Georgia Institute of Technology | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Memgen, Inc.
Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Health Technology |
